Advertisement

Tumor Biology

, Volume 35, Issue 2, pp 961–965 | Cite as

Murine double minute 2 rs2279744 polymorphism and hepatocellular carcinoma risk in East Asians: a meta-analysis

  • Yubin Liu
  • Sujuan Kuang
  • Jun Zheng
  • Jianghua Zheng
  • Haosheng Jin
  • Sicong Chen
  • Zhixiang Jian
Research Article

Abstract

Murine double minute 2 (MDM2) is a crucial negative regulator of p53 function through several mechanisms. There are many studies performed to assess the association between MDM2 rs2279744 polymorphism and hepatocellular carcinoma risk, but the impact of MDM2 rs2279744 polymorphism on hepatocellular carcinoma in East Asians is unclear owing to the inconsistent findings from previous studies. We conducted a comprehensive meta-analysis of epidemiological studies to shed some light on these contradicting results. We used pooled odds ratio (OR) with its 95 % confidence intervals (95 % CI) to assess the association. Overall, seven studies with a total of 4,993 subjects were finally included. The meta-analysis suggested that MDM2 rs2279744 polymorphism was significantly associated with increased risk of hepatocellular carcinoma in East Asians (G versus T: OR = 1.27, 95 % CI 1.06–1.52, P = 0.01; GG versus TT: OR = 1.59, 95 % CI 1.11–2.27, P = 0.01; GG/GT versus TT: OR = 1.41, 95 % CI 1.07–1.87, P = 0.02; GG versus TT/GT: OR = 1.32, 95 % CI 1.08–1.62, P = 0.008). Sensitivity analysis by excluding low-quality study still suggested that the association above was still significant. Thus, the findings from the meta-analysis support that MDM2 rs2279744 polymorphism is significantly associated with increased risk of hepatocellular carcinoma in East Asians.

Keywords

Hepatocellular carcinoma MDM2 Polymorphism Meta-analysis 

Notes

Acknowledgments

This work was supported by Guangdong province Science and Technology Plan Projects in 2008 (2008 b36002026).

Conflicts of interest

None

References

  1. 1.
    Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379(9822):1245–55.PubMedCrossRefGoogle Scholar
  2. 2.
    Ikeda Y, Shimada M, Hasegawa H, Gion T, Kajiyama K, Shirabe K, et al. Prognosis of hepatocellular carcinoma with diabetes mellitus after hepatic resection. Hepatology. 1998;27:1567–71.PubMedCrossRefGoogle Scholar
  3. 3.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRefGoogle Scholar
  4. 4.
    El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142:1264–73. e1261.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Ploss A, Dubuisson J. New advances in the molecular biology of hepatitis C virus infection: towards the identification of new treatment targets. Gut. 2012;61 Suppl 1:i25–35.PubMedCrossRefGoogle Scholar
  6. 6.
    Bruix J, Llovet JM. Major achievements in hepatocellular carcinoma. Lancet. 2009;373:614–6.PubMedCrossRefGoogle Scholar
  7. 7.
    Asim M, Malik A, Ahmad I, Khan NA, Kar P. Association of TNF alpha promoter polymorphism with an increased risk of hepatocellular carcinoma in north Indian population. Hepatol Int. 2011;5:428.Google Scholar
  8. 8.
    Wang B, Huang G, Wang D, Li A, Xu Z, Dong R, et al. Null genotypes of GSTM1 and GSTT1 contribute to hepatocellular carcinoma risk: evidence from an updated meta-analysis. J Hepatol. 2010;53:508–18.PubMedCrossRefGoogle Scholar
  9. 9.
    Kubbutat MHG, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature. 1997;387:299–303.PubMedCrossRefGoogle Scholar
  10. 10.
    Vousden KH, Prives C. P53 and prognosis: new insights and further complexity. Cell. 2005;120:7–10.PubMedGoogle Scholar
  11. 11.
    Cheok CF, Verma CS, Baselga J, Lane DP. Translating p53 into the clinic. Nat Rev Clin Oncol. 2011;8:25–37.PubMedCrossRefGoogle Scholar
  12. 12.
    Deisenroth C, Zhang Y. Ribosome biogenesis surveillance: probing the ribosomal protein-Mdm2-p53 pathway. Oncogene. 2010;29:4253–60.PubMedCrossRefGoogle Scholar
  13. 13.
    Lauria A, Tutone M, Ippolito M, Pantano L, Almerico AM. Molecular modeling approaches in the discovery of new drugs for anti-cancer therapy: the investigation of p53-MDM2 interaction and its inhibition by small molecules. Curr Med Chem. 2010;17:3142–54.PubMedCrossRefGoogle Scholar
  14. 14.
    Whibley C, Pharoah PD, Hollstein M. p53 polymorphisms: cancer implications. Nat Rev Cancer. 2009;9:95–107.PubMedCrossRefGoogle Scholar
  15. 15.
    Wilkening S, Bermejo JL, Hemminki K. MDM2 SNP309 and cancer risk: a combined analysis. Carcinogenesis. 2007;28:2262–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Dharel N, Kato N, Muroyama R, Moriyama M, Shao RX, Kawabe T, et al. MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C. Clin Cancer Res. 2006;12:4867–71.PubMedCrossRefGoogle Scholar
  17. 17.
    Jiang D, Yu L: P53 gene mutation, r72p polymorphism and mdm2 snp309 gene polymorphism and HCC risk and prognosis. Wanfang Doctoral Dissertation 2008;2008:2008.Google Scholar
  18. 18.
    Yoon YJ, Chang HY, Ahn SH, Kim JK, Park YK, Kang DR, et al. MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Carcinogenesis. 2008;29:1192–6.PubMedCrossRefGoogle Scholar
  19. 19.
    Leu JD, Lin IF, Sun YF, Chen SM, Liu CC, Lee YJ. Association between MDM2-SNP309 and hepatocellular carcinoma in Taiwanese population. World J Gastroenterol. 2009;15:5592–7.PubMedCrossRefGoogle Scholar
  20. 20.
    Tomoda T, Nouso K, Sakai A, Ouchida M, Kobayashi S, Miyahara K, et al. Genetic risk of hepatocellular carcinoma in patients with hepatitis C virus: a case control study. J Gastroenterol Hepatol. 2012;27:797–804.PubMedCrossRefGoogle Scholar
  21. 21.
    Wang X, Zhang X, Qiu B, Tang Y, Sun H, Ji H, et al. MDM2 SNP309T>G polymorphism increases susceptibility to hepatitis B virus-related hepatocellular carcinoma in a northeast Han Chinese population. Liver Int. 2012;32:1172–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Yang Y, Xia T, Li N, Zhang J, Cong W, Deng Q, et al. Combined effects of p53 and MDM2 polymorphisms on susceptibility and surgical prognosis in hepatitis B virus-related hepatocellular carcinoma. Protein Cell. 2013;4:71–81.PubMedCrossRefGoogle Scholar
  23. 23.
    Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMedGoogle Scholar
  24. 24.
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.PubMedCrossRefGoogle Scholar
  25. 25.
    Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.PubMedCrossRefGoogle Scholar
  26. 26.
    Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.PubMedCrossRefGoogle Scholar
  27. 27.
    He W, Long J, Xian L, Pang F, Su L, Wei S, et al. MDM2 SNP309 polymorphism is associated with lung cancer risk in women: a meta-analysis using METAGEN. Exp Ther Med. 2012;4:569–76.PubMedCentralPubMedGoogle Scholar
  28. 28.
    Ma Y, Bian J, Cao H. MDM2 SNP309 rs2279744 polymorphism and gastric cancer risk: a meta-analysis. PLoS One. 2013;8:e56918.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  • Yubin Liu
    • 1
  • Sujuan Kuang
    • 2
  • Jun Zheng
    • 1
  • Jianghua Zheng
    • 1
  • Haosheng Jin
    • 1
  • Sicong Chen
    • 1
  • Zhixiang Jian
    • 1
  1. 1.Hepatobiliary Surgery & General Surgery, Guangdong General HospitalGuangdong Academy of Medical SciencesGuangzhouChina
  2. 2.Central Laboratory, Guangdong General HospitalGuangdong Academy of Medical SciencesGuangzhouChina

Personalised recommendations